SEC Form 4 · accession 0001209191-19-002843
Kezar Life Sciences, Inc. · KZR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher J. Kirk
Officer — President and CSO · Director
Period of report
Jan 6, 2019
Accepted (ET)
Jan 8, 2019 · 5:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645666
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $22.85 | Jan 6, 2019 | A | 87,500 | A | — | Jan 5, 2029 | Common Stock | 87,500 | 87,500 | D |
Explanation of responses
- F1One forty-eighth (1/48th) of the shares shall vest on a monthly basis commencing on February 6, 2019, subject to the Reporting Person continuing to provide service through each such date.